Anti-CD38 antibody - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Anti-CD38 Antibody - Pipeline Insight, 2022” report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Anti-CD38 Antibody pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Anti-CD38 Antibody: Overview
CD38 is a small multifunctional glycoprotein (1) widely represented on lymphoid and myeloid lineages but absent from most mature resting lymphocytes. In many lymphoid tumors—including most cases of myeloma (2), many cases of AIDS-associated lymphoma (3), and many cases of post-transplant lymphoproliferations (4)—it is present on the cell surface in amounts which render it an attractive target for therapeutic antibody.
Function - CD38 is also known to have important enzymatic functions, acting as a nicotinamide adenine dinucleotide (NAD) degrading enzyme (NADase) in several tissues. Specifically, it breaks down NAD into nicotinamide and adenosine diphosphate ribose (ADPR) or, to a lesser extent, cyclic ADPR (cADPR). In this manner, CD38 regulates the homeostasis of NAD, a crucial cofactor in cell signaling and metabolism, while controlling the availability of its metabolites. ADPR acts as a second messenger in calcium signaling and can be further metabolized into the nucleoside adenosine.
Anti-CD38 Antibody - During the past years, therapies targeting CD38, a protein highly expressed on the surface of plasma cells, have helped fuel the rapidly growing treatment options for patients with multiple myeloma (MM). Investigators are seeking to build on that success by expanding uses for existing drugs and exploring novel strategies aimed at CD38 activity in MM.
Anti-CD38 Antibody Emerging Drugs Chapters
This segment of the Anti-CD38 Antibody report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anti-CD38 Antibody Emerging Drugs
Further product details are provided in the report……..
Anti-CD38 Antibody: Therapeutic Assessment
This segment of the report provides insights about the different Anti-CD38 Antibody drugs segregated based on following parameters that define the scope of the report, such as:
Anti-CD38 Antibody: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anti-CD38 Antibody therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anti-CD38 Antibody drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Anti-CD38 Antibody - Pipeline Insight, 2022” report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Anti-CD38 Antibody pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Anti-CD38 Antibody: Overview
CD38 is a small multifunctional glycoprotein (1) widely represented on lymphoid and myeloid lineages but absent from most mature resting lymphocytes. In many lymphoid tumors—including most cases of myeloma (2), many cases of AIDS-associated lymphoma (3), and many cases of post-transplant lymphoproliferations (4)—it is present on the cell surface in amounts which render it an attractive target for therapeutic antibody.
Function - CD38 is also known to have important enzymatic functions, acting as a nicotinamide adenine dinucleotide (NAD) degrading enzyme (NADase) in several tissues. Specifically, it breaks down NAD into nicotinamide and adenosine diphosphate ribose (ADPR) or, to a lesser extent, cyclic ADPR (cADPR). In this manner, CD38 regulates the homeostasis of NAD, a crucial cofactor in cell signaling and metabolism, while controlling the availability of its metabolites. ADPR acts as a second messenger in calcium signaling and can be further metabolized into the nucleoside adenosine.
Anti-CD38 Antibody - During the past years, therapies targeting CD38, a protein highly expressed on the surface of plasma cells, have helped fuel the rapidly growing treatment options for patients with multiple myeloma (MM). Investigators are seeking to build on that success by expanding uses for existing drugs and exploring novel strategies aimed at CD38 activity in MM.
Anti-CD38 Antibody Emerging Drugs Chapters
This segment of the Anti-CD38 Antibody report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anti-CD38 Antibody Emerging Drugs
- Felzartamab (MOR202): MorphoSys
- STI-6129: Sorrento Therapeutics
Further product details are provided in the report……..
Anti-CD38 Antibody: Therapeutic Assessment
This segment of the report provides insights about the different Anti-CD38 Antibody drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Anti-CD38 Antibody
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Anti-CD38 Antibody: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anti-CD38 Antibody therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anti-CD38 Antibody drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Anti-CD38 Antibody R&D. The therapies under development are focused on novel approaches for Anti-CD38 Antibody.
- Anti-CD38 Antibody Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Anti-CD38 Antibody drugs?
- How many Anti-CD38 Antibody drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Anti-CD38 Antibody?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Anti-CD38 Antibody therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Anti-CD38 Antibody and their status?
- What are the key designations that have been granted to the emerging drugs?
- MorphoSys
- CASI Pharmaceuticals
- TeneoFour
- Sorrento Therapeutics
- Sanofi
- Janssen Biotech
- Takeda
- Xencor
- Glenmark Pharmaceuticals
- Janssen
- Centrose
- Genmab
- Henlius
- Felzartamab (MOR202)
- CID 103
- Ab 68
- STI-6129
- Isatuximab
- Daratumumab
- Mezagitamab
- AMG 424
- GBR 1342
- TAK-573
- SAR442085
- HLX15
Introduction
Executive Summary
Anti-CD38 Antibody: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Anti-CD38 Antibody – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Anti-CD38 Antibody companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Anti-CD38 Antibody Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Felzartamab (MOR202): MorphoSys
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
STI-6129: Sorrento Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Ab 68: Teneobio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Anti-CD38 Antibody Key Companies
Anti-CD38 Antibody Key Products
Anti-CD38 Antibody- Unmet Needs
Anti-CD38 Antibody- Market Drivers and Barriers
Anti-CD38 Antibody- Future Perspectives and Conclusion
Anti-CD38 Antibody Analyst Views
Anti-CD38 Antibody Key Companies
Appendix
Executive Summary
Anti-CD38 Antibody: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Anti-CD38 Antibody – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Anti-CD38 Antibody companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Anti-CD38 Antibody Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Felzartamab (MOR202): MorphoSys
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
STI-6129: Sorrento Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Ab 68: Teneobio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Anti-CD38 Antibody Key Companies
Anti-CD38 Antibody Key Products
Anti-CD38 Antibody- Unmet Needs
Anti-CD38 Antibody- Market Drivers and Barriers
Anti-CD38 Antibody- Future Perspectives and Conclusion
Anti-CD38 Antibody Analyst Views
Anti-CD38 Antibody Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Anti-CD38 Antibody
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Anti-CD38 Antibody
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Anti-CD38 Antibody
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Anti-CD38 Antibody
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
